X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (190) 190
microbiology (142) 142
infectious diseases (126) 126
virology (108) 108
hiv infections - virology (100) 100
hiv infections - drug therapy (94) 94
biochemistry (91) 91
beer (89) 89
chemistry (89) 89
enzymology (89) 89
metallurgy (89) 89
mutation or genetic engineering (89) 89
spirits (89) 89
vinegar (89) 89
wine (89) 89
female (82) 82
hiv-1 - genetics (81) 81
male (81) 81
immunology (78) 78
adult (76) 76
organic chemistry (75) 75
testing (73) 73
culture media (72) 72
compositions thereof (71) 71
microorganisms or enzymes (71) 71
peptides (71) 71
propagating, preserving or maintaining microorganisms (71) 71
hiv-1 - drug effects (68) 68
investigating or analysing materials by determining theirchemical or physical properties (68) 68
measuring (68) 68
physics (68) 68
index medicus (66) 66
human necessities (63) 63
hygiene (63) 63
medical or veterinary science (63) 63
preparations for medical, dental, or toilet purposes (63) 63
compositions or test papers therefor (62) 62
condition-responsive control in microbiological orenzymological processes (62) 62
measuring or testing processes involving enzymes, nucleicacids or microorganisms (62) 62
processes of preparing such compositions (62) 62
mutation (57) 57
genotype (50) 50
viral load (50) 50
hiv (49) 49
pharmacology & pharmacy (47) 47
middle aged (46) 46
anti-hiv agents - pharmacology (45) 45
anti-hiv agents - therapeutic use (44) 44
aids (39) 39
drug resistance, viral - genetics (38) 38
nucleosides (38) 38
nucleotides (37) 37
derivatives thereof (36) 36
nucleic acids (36) 36
sugars (36) 36
antiretroviral therapy (34) 34
rna, viral - blood (33) 33
cd4 lymphocyte count (31) 31
infection (30) 30
hiv-1 (28) 28
mutations (28) 28
processes using microorganisms (28) 28
protease inhibitors (28) 28
drug resistance, viral (26) 26
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (26) 26
molecular sequence data (26) 26
drug resistance (25) 25
drug therapy, combination (25) 25
hiv infection (25) 25
hiv-1 - isolation & purification (25) 25
specific therapeutic activity of chemical compounds ormedicinal preparations (25) 25
hiv infections - immunology (24) 24
hiv-2 - genetics (24) 24
human immunodeficiency virus--hiv (24) 24
resistance (24) 24
therapy (24) 24
hiv-2 (23) 23
reverse transcriptase inhibitors - therapeutic use (23) 23
treatment outcome (23) 23
hiv infections - epidemiology (22) 22
antiviral agents (21) 21
reverse transcriptase inhibitors - pharmacology (21) 21
aids/hiv (20) 20
drug therapy (20) 20
france (20) 20
general tagging of cross-sectional technologies spanning over several sections of the ipc (20) 20
general tagging of new technological developments (20) 20
hiv protease inhibitors - pharmacology (20) 20
prevalence (20) 20
technical subjects covered by former uspc (20) 20
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (20) 20
technical subjects covered by former uspc cross-reference artcollections [xracs] and digests (20) 20
viruses (20) 20
antiretroviral drugs (19) 19
cohort studies (19) 19
hiv reverse transcriptase - genetics (19) 19
immunodeficiency-virus type-1 (18) 18
zidovudine (18) 18
drug-resistance (17) 17
hiv protease inhibitors - therapeutic use (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 7/2008, Volume 47, Issue 2, pp. 266 - 285
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, p. e0134904
Background Maraviroc activity against HIV-2, a virus naturally resistant to different HIV-1 antiretroviral drugs, has been recently demonstrated. The aim of... 
CELLS | MULTIDISCIPLINARY SCIENCES | REVERSE-TRANSCRIPTASE | IMMUNODEFICIENCY-VIRUS TYPE-2 | PHENOTYPIC SUSCEPTIBILITY | SALVAGE THERAPY | CORECEPTOR USAGE | INFECTION | INHIBITORS | Anti-HIV Agents - pharmacology | Leukocytes, Mononuclear - metabolism | CCR5 Receptor Antagonists - pharmacology | CCR5 Receptor Antagonists - therapeutic use | Coculture Techniques | Cyclohexanes - pharmacology | Humans | Receptors, CCR2 - antagonists & inhibitors | Cyclohexanes - therapeutic use | Receptors, CCR5 - metabolism | HIV Infections - pathology | Phytohemagglutinins - pharmacology | HIV-2 - physiology | Anti-HIV Agents - therapeutic use | Imidazoles - therapeutic use | Triazoles - therapeutic use | Virus Replication - drug effects | Leukocytes, Mononuclear - drug effects | HIV-2 - isolation & purification | HIV Infections - virology | Cells, Cultured | Imidazoles - pharmacology | HIV-2 - drug effects | Triazoles - pharmacology | Phenotype | Receptors, CCR2 - metabolism | Receptors, CCR5 - chemistry | HIV Infections - drug therapy | Leukocytes, Mononuclear - cytology | Highly active antiretroviral therapy | Care and treatment | Patient outcomes | Research | Diagnosis | HIV infection | Risk factors | Tropism | CC chemokine receptors | Antiretroviral drugs | CCR5 protein | Phenotypes | Blood & organ donations | Cultivation | Clinical isolates | Viruses | Infections | CCR2 protein | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Cell lines | Peripheral blood mononuclear cells | Drug dosages | Strains (organisms) | Monocyte chemoattractant protein 1 | Viral infections | Life Sciences | Medication | Microbiology and Parasitology | Pharmaceutical sciences | Virology | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article
Journal of Virology, ISSN 0022-538X, 05/2009, Volume 83, Issue 10, pp. 4854 - 4860
Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley... 
Virus-Cell Interactions
Journal Article
Journal of the International AIDS Society, ISSN 1758-2652, 01/2014, Volume 17, Issue 1, pp. 19070 - n/a
Introduction We compared the effectiveness of tenofovir/emtricitabine (TDF/FTC) combined with either lopinavir/r (LPV/r) or another recommended third drug in... 
effectiveness | first‐line therapy | HIV infection | antiretroviral therapy | propensity score | Hiv infection | Effectiveness | Propensity score | First-line therapy | Antiretroviral therapy | first-line therapy | INFECTIOUS DISEASES | NAIVE HIV-1-INFECTED PATIENTS | ONCE-DAILY ATAZANAVIR/RITONAVIR | INITIAL TREATMENT | IMMUNOLOGY | COMBINATION | HIV | EFAVIRENZ | TWICE-DAILY LOPINAVIR/RITONAVIR | TENOFOVIR | Emtricitabine | Adenine - analogs & derivatives | Prospective Studies | Organophosphonates - therapeutic use | Humans | Middle Aged | Male | CD4 Lymphocyte Count | Viral Load | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Treatment Failure | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Lopinavir - therapeutic use | Antiretroviral Therapy, Highly Active - methods | France | Deoxycytidine - analogs & derivatives | Cohort Studies | Highly active antiretroviral therapy | Pharmacology, Experimental | Lopinavir | Drug therapy | Comparative analysis | Methods | Studies | Antiretroviral drugs | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Clinical trials | Infections | Hospitalization | Pharmaceutical industry | Patients | Morbidity | Clinical outcomes | Life Sciences | Human health and pathology | Pharmacology | Infectious diseases | Pharmaceutical sciences
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2013, Volume 8, Issue 3, p. e59205
Objective: The aim of our study was to assess a possible association between plasma inflammatory biomarkers (CRP, IL-6, soluble CD14) and the extent of... 
INDIVIDUALS | RISK | HIV-INFECTION | MULTIDISCIPLINARY SCIENCES | ACTIVE ANTIRETROVIRAL THERAPY | DISEASE PROGRESSION | Liver Cirrhosis - etiology | Liver Cirrhosis - diagnosis | C-Reactive Protein | Cross-Sectional Studies | Enzyme-Linked Immunosorbent Assay | Humans | Logistic Models | Alanine Transaminase - blood | Liver Cirrhosis - blood | Biomarkers - blood | Liver Cirrhosis - enzymology | Coinfection - complications | Interleukin-6 | Lipopolysaccharide Receptors | CD4-Positive T-Lymphocytes - immunology | Aspartate Aminotransferases - blood | HIV Infections - complications | Hepatitis C - complications | Medical research | Enzymes | RNA | Liver | Aspartate | Infection control | Infection | Analysis | Fibrosis | Medicine, Experimental | Biological markers | Hepatitis C virus | Health aspects | HIV infection | Liver cirrhosis | Enzyme-linked immunosorbent assay | CD14 antigen | Interleukin 6 | Confidence intervals | Regression models | Cell activation | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Kits | Antiretroviral drugs | Alanine | Statistical analysis | Mortality | Inflammation | Regression analysis | Ribonucleic acid--RNA | Patients | CD4 antigen | Cirrhosis | Monocytes | Alanine transaminase | Biomarkers | Aspartate aminotransferase | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | HIV | Human immunodeficiency virus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 7/2003, Volume 37, Issue 1, pp. 113 - 128
Journal Article
AIDS, ISSN 0269-9370, 10/2018
OBJECTIVE:HIV-1 and HIV-2 differ notably in their epidemiology, with worldwide HIV-1 spread and HIV-2 mainly confined to West Africa. Natural killer (NK) cells... 
Journal Article
Journal Article
PLoS pathogens, ISSN 1553-7366, 05/2019, Volume 15, Issue 5, p. e1007758
Journal Article